Comparative characterization of stem cell marker expression, metabolic activity and resistance to doxorubicin in adherent and spheroid cells derived from the canine prostate adenocarcinoma cell line CT1258

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 1917-1927

  Liu, Wen ^a,b   Moulay, Mohammed ^a   Willenbrock, Saskia ^a   Roolf, Catrin ^b   Junghanss, Christian ^b   Ngenazahayo, Anaclet ^c   Nolte, Ingo ^a   Escobar, Hugo Murua ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Cancer stem cell marker; Canine cancer stem cells; Prostate cancer; Spheroid cell clusters

Indexed keywords

ALPHA6 INTEGRIN; BETA ACTIN; BIOLOGICAL MARKER; CD133 ANTIGEN; DOXORUBICIN; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RETINOIC ACID INDUCIBLE PROTEIN I; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; DOG; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPHEROID CELL; UPREGULATION; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MULTICELLULAR SPHEROID; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOGS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA6; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; SPHEROIDS, CELLULAR;

EID: 84928384728     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Society AC: Cancer Facts & Figures 2013. Atlanta: American Cancer Society 2013.
2. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, and Tindall DJ: Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 36: 64-67, 1998.
3. Waters DJ, Patronek GJ, Bostwick DG, and Glickman LT: Compa ring the age at prostate cancer diagnosis in humans and dogs. Journal Of the National Cancer Institute 88: 1686-1687, 1996.
4. MacEwen EG: Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 9: 125-136, 1990.
5. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, and Waters DJ: Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate 45: 173-183, 2000.
6. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, and Contag CH: Animal models of bone metastasis. Cancer 97: 748-757, 2003.
7. Lawrence JA SC: Tumors of the Male Reproductive System 2013.
8. Axiak SM and Bigio A: Canine prostatic carcinoma. Compend Contin Educ Vet 34: E1-5, 2012.
9. Fan TM adL: Tumors of the Male Reproductive System. in Small Animal Clinical OncologyWB edited by Withrow and Vaul DM Saunders Elsevier 4: 637-649, 2007.
10. Leroy BE and Northrup N: Prostate cancer in dogs: comparative and clinical aspects. Vet J 180: 149-162, 2009.
11. Bell FW, Klausner JS, Hayden DW, Feeney DA, and Johnston SD: Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). J Am Vet Med Assoc 199: 1623-1630, 1991.
12. Winter SF, Cooper AB, and Greenberg NM: Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 6: 204-211, 2003.
13. Simmons J, Elshafae S, Keller E, McCauley L, and Rosol T: Review of Animal Models of Prostate Cancer Bone Metastasis. Veterinary Sciences 1: 16-39, 2014.
14. Rowell JL, McCarthy DO, and Alvarez CE: Dog models of naturally occurring cancer. Trends Mol Med 17: 380-388, 2011.
15. Argyle DJ: Prostate cancer in dogs and men: a unique opportunity to study the disease. Vet J 180: 137-138, 2009.
16. Navone NM, Logothetis CJ, von Eschenbach AC, and Troncoso P: Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 17: 361-371, 1998.
17. Russell PJ and Voeks DJ: Animal models of prostate cancer. Methods Mol Med 81: 89-112, 2003.
18. Seachrist L: Man's best friend may be companion in cancer research. J Natl Cancer Inst 85: 1455-1456, 1993.
19. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, and Bostwick DG: Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 30: 92-97, 1997.
20. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, and Withrow S: The dog as a cancer model. Nat Biotechnol 24: 1065-1066, 2006.
21. Lawson DA and Witte ON: Stem cells in prostate cancer initiation and progression. J Clin Invest 117: 2044-2050, 2007.
22. Diehn M and Clarke MF: Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98: 1755-1757, 2006.
23. Sakariassen PO, Immervoll H, and Chekenya M: Cancer stem cells as mediators of treatment resistance in brain tumors: Status and controversies. Neoplasia 9: 882-892, 2007.
24. Blacking TM WH, Argyle DJ: is cancer a stem cell disease? theory, evidence and implication. Veterinary and Comparative Oncology, 5, 2, 76-89, 2007
25. Argyle DJ KC: Tumor Biology and Metastasis2013.
26. Gilbert CA and Ross AH: Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 108: 1031-1038, 2009.
27. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, and Los M: Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 14: 450-460, 2008.
28. Gu MJ and Jang BI: Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangio car cinoma. Pathol Oncol Res 20: 655-660, 2014.
29. Bin Z, Guangbo Z, Yan G, Huan Z, Desheng L, and Xueguang Z: Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients. J Surg Res 188: 396-403, 2014.
30. Tang YL, Fan YL, Jiang J, Li KD, Zheng M, Chen W, Ma XR, Geng N, Chen QM, Chen Y, and Liang XH: C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget 5: 1491-1501, 2014.
31. Sidney LE, Branch MJ, Dunphy SE, Dua HS, and Hopkinson A: Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 32: 1380-1389, 2014.
32. Mostert B, Kraan J, Sieuwerts AM, van der Spoel P, Bolt-de Vries J, Prager-van der Smissen WJ, Smid M, Timmermans AM, Martens JW, Gratama JW, Foekens JA, and Sleijfer S: CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 319: 49-55, 2012.
33. Leong KG, Wang BE, Johnson L, and Gao WQ: Generation of a prostate from a single adult stem cell. Nature 456: 804-808, 2008.
34. Yamamoto H MJ, Dasgupta P, Chandra A, Popert R, Freeman A, Ahmed A.: CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. PLoS One 7: 1-11, 2012.
35. Magri L, Gacias M, Wu M, Swiss VA, Janssen WG, and Casaccia P: c-Myc-dependent transcriptional regulation of cell cycle and nucleosomal histones during oligodendrocyte differentiation. Neuroscience 276: 72-86, 2014.
36. Wang Z, Oron E, Nelson B, Razis S, and Ivanova N: Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell 10: 440-454, 2012.
37. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, Repass J, Zaehres H, Shen JJ, and Tang DG: NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 30: 3833-3845, 2011.
38. Geissler V, Altmeyer S, Stein B, Uhlmann-Schiffler H, and Stahl H: The RNA helicase Ddx5/p68 binds to hUpf3 and enhances NMD of Ddx17/p72 and Smg5 mRNA. Nucleic Acids Res 41: 7875-7888, 2013.
39. Ai YSaW: Function of KLF4 in Stem Cell Biology Chapter 15: Pluripotent Stem Cells book edited by Deepa Bhartiya and Nibedita Lenka, ISBN 978-953-51-1192-4, Published: August 28, 2013 under CC BY 30 license 2013.
40. Jiang P and Zhang D: Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic develop ment, and cancer. Int J Mol Sci 14: 21551-21560, 2013.
41. Radzisheuskaya A, Chia Gle B, dos Santos RL, Theunissen TW, Castro LF, Nichols J, and Silva JC: A defined Oct4 level governs cell state transitions of pluripotency entry and differentiation into all embryonic lineages. Nat Cell Biol 15: 579-590, 2013.
42. Trapasso S and Allegra E: Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biologics 6: 379-383, 2012.
43. Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
44. Yu SC and Bian XW: Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev 5: 66-71, 2009.
45. Wang S, Huang S, Zhao X, Zhang Q, Wu M, Sun F, Han G, and Wu D: Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples. Int J Clin Exp Pathol 7: 184-193, 2014.
46. Moulay M, Liu W, Willenbrock S, Sterenczak KA, Carlson R, Ngezahayo A, Murua Escobar H, and Nolte I: Evaluation of stem cell marker gene expression in canine prostate carcinoma- and prostate cyst-derived cell lines. Anticancer Res 33: 5421-5431, 2013.
47. Winkler S, Murua Escobar H, Eberle N, Reimann-Berg N, Nolte I, and Bullerdiek J: Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype. J Hered 96: 782-785, 2005.
48. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, and Jeter C: Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 46: 1-14, 2007.
49. Wang L, Huang X, Zheng X, Wang X, Li S, Zhang L, Yang Z, and Xia Z: Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy. Int J Biol Sci 9: 472-479, 2013.
50. Fan X, Liu S, Su F, Pan Q, and Lin T: Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol Oncol 30: 314-318, 2012.
51. Blacking TM, Waterfall M, Samuel K, and Argyle DJ: Flow cytometric techniques for detection of candidate cancer stem cell subpopulations in canine tumour models. Vet Comp Oncol 10: 252-273, 2012.
52. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, and Rhim JS: Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161, 2007.
53. Paronetto MP, Farini D, Sammarco I, Maturo G, Vespasiani G, Geremia R, Rossi P, and Sette C: Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol 164: 1243-1251, 2004.
54. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, and Stadler WM: Diffusion -weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197: 1382-1390, 2011.
55. Kuranda K, Berthon C, Lepretre F, Polakowska R, Jouy N, and Quesnel B: Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor-like state. J Cell Biochem 112: 1277-1285, 2011.
56. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, and Corte G: SOX2 silencing in glioblastoma tumor-initiating cells causes stop of pro li feration and loss of tumorigenicity. Stem Cells 27: 40-48, 2009.
57. + cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
58. Nakano I, Paucar AA, Bajpai R, Dougherty JD, Zewail A, Kelly TK, Kim KJ, Ou J, Groszer M, Imura T, Freije WA, Nelson SF, Sofroniew MV, Wu H, Liu X, Terskikh AV, Geschwind DH, and Kornblum HI: Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 170: 413-427, 2005.
59. Hebbard LW, Maurer J, Miller A, Lesperance J, Hassell J, Oshima RG, and Terskikh AV: Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo . Cancer Res 70: 8863-8873, 2010.
60. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilber tson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS, Terskikh AV, and Kornblum HI: Maternal embry onic leucine zipper kinase is a key regulator of the prolife ration of malignant brain tumors, including brain tumor stem cells. J Neurosci Res 86: 48-60, 2008.
61. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
62. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, and Collins AT: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117: 3539-3545, 2004.
63. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, Cher ML, and Bonfil RD: C-kit and its ligand stem cell factor: potential contribu tion to prostate cancer bone metastasis. Neoplasia 10: 996-1003, 2008.
64. Sroka I.C PGD, Nagle R.B, Porreca F, King T, Pestano G, Futscher B.W, Gard J.M, Riley J, Sathyanarayana U.G and Cress A.E: Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer. The Open Prostate Cancer Journal, 2: 59-66, 2009.
65. Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, and Robson CN: The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 68: 7938-7946, 2008.
66. Le Page Y, Chartrain I, Badouel C, and Tassan JP: A functional analysis of MELK in cell division reveals a transition in the mode of cytokinesis during Xenopus development. J Cell Sci 124: 958-968, 2011.
67. Rowland BD, Bernards R, and Peeper DS: The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 7: 1074-1082, 2005.
68. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, Liu Y, Lv D, Liu CH, Tan X, Xiang R, and Li N: SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 3: 230-238, 2011.
69. Yu KR, Yang SR, Jung JW, Kim H, Ko K, Han DW, Park SB, Choi SW, Kang SK, Scholer H, and Kang KS: CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells 30: 876-887, 2012.
70. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, and Abate-Shen C: B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advan ced prostate cancer. Cancer Res 72: 4765-4776, 2012.
71. Ju X, Ertel A, Casimiro MC, Yu Z, Meng H, McCue PA, Walters R, Fortina P, Lisanti MP, and Pestell RG: Novel oncogene-induced metastatic prostate cancer cell lines define human pro state cancer progression signatures. Cancer Res 73: 978-989, 2013.
72. Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, Dorsch M, Reimann-Berg N, Hedrich HJ, Bullerdiek J, and Nolte I: Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer 8: 240, 2008.
73. Emadi Baygi M, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W, and Schulz WA: Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol 31: 297-307, 2010.
74. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S, and Schulz WA: Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol 26: 553-567, 2010.
75. Cheng I, Plummer SJ, Neslund-Dudas C, Klein EA, Casey G, Rybicki BA, and Witte JS: Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 19: 2124-2132, 2010.
76. Golbert DC, Correa-de-Santana E, Ribeiro-Alves M, de Vasconcelos AT, and Savino W: ITGA6 gene silencing by RNA interference modulates the expression of a large number of cell migration-related genes in human thymic epithelial cells. BMC Genomics 14 Suppl 6: S3, 2013.
77. Dean M, Fojo T, and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
78. Tennant DA, Duran RV, and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277, 2010.
79. Menendez JA, Joven J, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, Martin-Castillo B, Lopez-Bonet E, Alarcon T, and Vazquez-Martin A: The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 12: 1166-1179, 2013.
80. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH, and Huang P: Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ 21: 124-135, 2014.